Standout Papers
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study (2013)
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study (2014)
Immediate Impact
6 from Science/Nature 67 standout
Citing Papers
Mechanisms of long COVID and the path toward therapeutics
2024 Standout
Platinum Nanoparticles Regulated V2C MXene Nanoplatforms with NIR‐II Enhanced Nanozyme Effect for Photothermal and Chemodynamic Anti‐Infective Therapy
2024 Standout
Works of Clare Brennan being referenced
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
2014 Standout
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
2013
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Clare Brennan | 1304 | 1025 | 291 | 338 | 20 | 1.5k | |
| Gildon Beall | 1263 | 875 | 474 | 384 | 40 | 2.1k | |
| Trevor Hawkins | 969 | 714 | 361 | 214 | 29 | 1.4k | |
| Barbara Gripshover | 794 | 619 | 286 | 408 | 45 | 1.2k | |
| Michael E. Abram | 1109 | 749 | 414 | 273 | 35 | 1.5k | |
| Xuelian Wei | 1602 | 1020 | 251 | 853 | 31 | 2.0k | |
| James Hellinger | 1339 | 807 | 731 | 324 | 29 | 1.7k | |
| Carlo Torti | 1121 | 901 | 267 | 309 | 61 | 1.4k | |
| Cindy Vavro | 1323 | 1126 | 278 | 302 | 24 | 1.5k | |
| Anna Bonjoch | 1305 | 955 | 329 | 794 | 62 | 1.8k | |
| Marshall W. Fordyce | 1442 | 949 | 435 | 495 | 30 | 1.8k |
All Works
Loading papers...